Moderna, Inc.
MRNA
$53.57
$1.863.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.13% | -46.54% | -38.04% | -48.50% | -66.42% |
| Total Other Revenue | 14.29% | 2.38% | -50.88% | -- | 55.56% |
| Total Revenue | -29.81% | -45.44% | -41.08% | -35.33% | -65.64% |
| Cost of Revenue | -34.07% | -38.95% | -38.70% | -18.38% | -20.30% |
| Gross Profit | 38.66% | -96.21% | 38.17% | 15.52% | -288.03% |
| SG&A Expenses | -12.25% | -4.63% | -14.18% | -22.63% | -25.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.61% | -33.95% | -34.60% | -19.19% | -21.14% |
| Operating Income | 31.22% | -271.43% | 33.46% | 17.06% | -20,866.67% |
| Income Before Tax | 32.52% | -990.48% | 36.04% | 17.25% | -1,791.43% |
| Income Tax Expenses | 142.19% | 62.50% | -- | -30.00% | 56.46% |
| Earnings from Continuing Operations | 26.25% | -1,638.46% | 35.50% | 17.36% | -616.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.25% | -1,638.46% | 35.50% | 17.36% | -616.13% |
| EBIT | 31.22% | -271.43% | 33.46% | 17.06% | -20,866.67% |
| EBITDA | 33.39% | -1,055.56% | 35.70% | 17.80% | -670.19% |
| EPS Basic | 27.57% | -1,617.16% | 36.16% | 18.22% | -610.73% |
| Normalized Basic EPS | 33.38% | -728.54% | 35.54% | 17.65% | -1,364.08% |
| EPS Diluted | 27.65% | -1,809.33% | 36.16% | 18.22% | -637.74% |
| Normalized Diluted EPS | 33.38% | -751.28% | 35.54% | 17.65% | -1,410.10% |
| Average Basic Shares Outstanding | 1.82% | 1.30% | 1.04% | 1.05% | 1.05% |
| Average Diluted Shares Outstanding | 1.82% | -2.26% | 1.04% | 1.05% | -2.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |